Osimertinib improves survival after surgery for non-small cell lung cancer

A new Yale-led study finds improved survival rates and reduced risk of recurrence of non-small cell lung cancer with the drug osimertinib following surgery.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news